1-6 of 6
Megumi Aizawa-Abe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

1028-P: Is Once-Weekly GLP-1 Receptor Agonist a Reasonable Option for Glucocorticoid-Induced Hyperglycemia? Twelve-Week Efficacy and Safety of Dulaglutide vs. Sitagliptin in Patients with Diabetes on Routine Glucocorticoid Treatment

SATOSHI YOSHIJI, YORIHIRO IWASAKI, KANAKO IWASAKI, MEGUMI AIZAWA-ABE, SACHIKO HONJO, YOSHIHARU WADA, JUN FUJIKAWA, AKIHIRO HAMASAKI
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1028-P
https://doi.org/10.2337/db19-1028-P
Published: 01 June 2019
View article titled, 1028-P: Is Once-Weekly GLP-1 Receptor Agonist a Reasonable Option for Glucocorticoid-Induced Hyperglycemia? Twelve-Week Efficacy and Safety of Dulaglutide vs. Sitagliptin in Patients with Diabetes on Routine Glucocorticoid Treatment
Meeting Abstracts

2343-PUB: Reduction of HbA1c after SGLT2 Inhibitors Correlate with Change in Plasma Osmolarity but Not with Elevation of Hematocrit in Japanese Patients with Type 2 Diabetes

YOSHIHARU WADA, YOSHIYUKI HAMAMOTO, YOSHIHISA NAKATANI, JUN FUJIKAWA, YORIHIRO IWASAKI, SATOSHI YOSHIJI, MEGUMI AIZAWA-ABE, KANAKO IWASAKI, SACHIKO HONJO, AKIHIRO HAMASAKI
Journal: Diabetes
Diabetes 2019;68(Supplement_1):2343-PUB
https://doi.org/10.2337/db19-2343-PUB
Published: 01 June 2019
View article titled, 2343-PUB: Reduction of HbA1c after SGLT2 Inhibitors Correlate with Change in Plasma Osmolarity but Not with Elevation of Hematocrit in Japanese Patients with Type 2 Diabetes
Meeting Abstracts

The Elevation of Hematocrit after Administration of SGLT2 Inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes

YOSHIHARU WADA, YOSHIYUKI HAMAMOTO, YORIHIRO IWASAKI, YOSHIHISA NAKATANI, JUN FUJIKAWA, SACHIKO HONJO, MEGUMI AIZAWA-ABE, AKIHIRO HAMASAKI
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1178-P
https://doi.org/10.2337/db18-1178-P
Published: 01 July 2018
View article titled, The Elevation of Hematocrit after Administration of SGLT2 Inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes
Journal Articles

Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats

Valentino Gumbilai, Ken Ebihara, Megumi Aizawa-Abe, Chihiro Ebihara, Mingming Zhao, Yuji Yamamoto, Tomoji Mashimo, Kiminori Hosoda, Tadao Serikawa, Kazuwa Nakao
Journal: Diabetes
Diabetes 2016;65(10):2954–2965
https://doi.org/10.2337/db15-1422
Published: 05 July 2016
View article titled, Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats
Open the PDF for Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats in another window
Includes: Supplementary data
Journal Articles

Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in a Mouse Model of Lipoatrophic Diabetes

Ken Ebihara, Yoshihiro Ogawa, Hiroaki Masuzaki, Mitsuyo Shintani, Fumiko Miyanaga, Megumi Aizawa-Abe, Tatsuya Hayashi, Kiminori Hosoda, Gen Inoue, Yasunao Yoshimasa, Oksana Gavrilova, Marc L. Reitman, Kazuwa Nakao
Journal: Diabetes
Diabetes 2001;50(6):1440–1448
https://doi.org/10.2337/diabetes.50.6.1440
Published: 01 June 2001
View article titled, Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in a Mouse Model of Lipoatrophic Diabetes
Open the PDF for Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in a Mouse Model of Lipoatrophic Diabetes in another window
Journal Articles

Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway

Mitsuyo Shintani, Yoshihiro Ogawa, Ken Ebihara, Megumi Aizawa-Abe, Fumiko Miyanaga, Kazuhiko Takaya, Tatsuya Hayashi, Gen Inoue, Kiminori Hosoda, Masayasu Kojima, Kenji Kangawa, Kazuwa Nakao
Journal: Diabetes
Diabetes 2001;50(2):227–232
https://doi.org/10.2337/diabetes.50.2.227
Published: 01 February 2001
View article titled, Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway
Open the PDF for Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway in another window